glp-1 news Science's 2023 Breakthrough: Agonists Show Promise Against Obesity-Associated Disease Could Weight Loss GLP-1 Drugs

For example, using a mouse model of Huntingtons disease, they found that exendin-4 reduces the accumulation of the mutant huntingtin protein, which is implicated in the diseases onset and progression

They reduce hemoglobin A 1c (HbA 1c ), weight, major cardiovascular events, and renal decline

The hoops we have to jump through are frustrating. Recognizing the growing demand and inequities, the Biden administration has proposed a $35 billion initiative over 10 years to expand Medicare and Medicaid coverage for obesity drugs

doi: 10.1016/j.appet.2008.12.003, 49 GearhardtA

The findings suggest semaglutide could become an important tool for clinicians treating both CKD and type 2 diabetes, according to Matthew Weir, MD, professor and chief of the division of nephrology at University of Maryland School of Medicine